Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | IDH2 | P48735 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 9/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17354476 | 0.90 | LMNA (0.36) | — | |
| SCHEMBL13725 | 0.90 | IDH2 (0.38) | ABL1IDH2IDH1KITKDR | |
| SCHEMBL13706 | 0.89 | KIT (0.38) | ABL1IDH2IDH1KITKDR | |
| SCHEMBL14075 | 0.89 | KIT (0.38) | ABL1IDH2IDH1KITKDR | |
| SCHEMBL13602 | 0.84 | KDR (0.39) | ABL1IDH2IDH1KITKDR | |
| SCHEMBL14853463 | 0.84 | HTT (0.32) | KDR | |
| SCHEMBL14147 | 0.82 | KDR (0.38) | ABL1IDH2IDH1KITKDR | |
| SCHEMBL14144 | 0.81 | KDR (0.38) | ABL1IDH2IDH1KITKDR | |
| SCHEMBL17486551 | 0.80 | IGF1R (0.35) | — | |
| SCHEMBL14853169 | 0.80 | RAB9A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | ABL1 2715/4885IDH2 3459/4885IDH1 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.